Suggestions for the prevention of Clostridioides difficile spread within outpatient hemodialysis facilities.


Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
05 2021
Historique:
received: 05 11 2020
revised: 23 01 2021
accepted: 04 02 2021
pubmed: 6 3 2021
medline: 22 6 2021
entrez: 5 3 2021
Statut: ppublish

Résumé

Clostridioides difficile infections (CDIs) cause substantial morbidity and mortality. Patients on maintenance hemodialysis are 2 to 2.5 times more likely to develop CDI, with mortality rates 2-fold higher than the general population. Hospitalizations due to CDI among the maintenance hemodialysis population are high, and the frequency of antibiotic exposures and hospitalizations may contribute to CDI risk. In this report, a panel of experts in clinical nephrology, infectious diseases, and infection prevention provide guidance, based on expert opinion and published literature, aimed at preventing the spread of CDI in outpatient hemodialysis facilities.

Identifiants

pubmed: 33667504
pii: S0085-2538(21)00270-2
doi: 10.1016/j.kint.2021.02.028
pmc: PMC10506371
mid: NIHMS1930764
pii:
doi:

Types de publication

Editorial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1045-1053

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Références

Clin Infect Dis. 1994 Feb;18(2):181-7
pubmed: 8161624
Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1389-1397
pubmed: 30139804
Clin Infect Dis. 2019 Apr 8;68(8):1343-1350
pubmed: 30668844
Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):63-67
pubmed: 25060801
J Nat Sci. 2015 Apr;1(4):
pubmed: 25879082
Infect Control Hosp Epidemiol. 2018 Dec;39(12):1400-1405
pubmed: 30253815
Infect Control Hosp Epidemiol. 1998 May;19(5):333-6
pubmed: 9613694
Arch Intern Med. 2011 Jan 10;171(1):32-8
pubmed: 21220658
Infect Control Hosp Epidemiol. 2007 Aug;28(8):920-5
pubmed: 17620238
Infect Dis Clin North Am. 2016 Dec;30(4):999-1012
pubmed: 27660089
Am J Kidney Dis. 2018 Jan;71(1):123-132
pubmed: 29162336
Clin J Am Soc Nephrol. 2018 Apr 6;13(4):666-668
pubmed: 29567862
Mayo Clin Proc. 2012 Nov;87(11):1046-53
pubmed: 23127731
Nephrology (Carlton). 2010 Jun;15(4):471-5
pubmed: 20609100
J Infect Dis. 1981 Jan;143(1):42-50
pubmed: 7217711
MMWR Recomm Rep. 2001 Apr 27;50(RR-5):1-43
pubmed: 11349873
Infect Control Hosp Epidemiol. 2015 Aug;36(8):972-4
pubmed: 25913501
N Engl J Med. 1989 Jan 26;320(4):204-10
pubmed: 2911306
J Clin Invest. 2014 Oct;124(10):4182-9
pubmed: 25036699
Infect Control Hosp Epidemiol. 2014 Jun;35(6):628-45
pubmed: 24799639
J Antimicrob Chemother. 2008 Sep;62(3):601-7
pubmed: 18468995
Infect Control Hosp Epidemiol. 2006 May;27(5):479-83
pubmed: 16671029
Infect Control Hosp Epidemiol. 2013 Apr;34(4):349-57
pubmed: 23466906
Infect Control Hosp Epidemiol. 2010 Jan;31(1):21-7
pubmed: 19929371
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48
pubmed: 29462280
Am J Infect Control. 2013 May;41(5):390-3
pubmed: 23622704
Future Microbiol. 2014;9(4):475-86
pubmed: 24810347
Infect Control Hosp Epidemiol. 1996 Mar;17(3):180-2
pubmed: 8708361
Infect Control Hosp Epidemiol. 2010 Jan;31(1):89-91
pubmed: 19929691
Dig Dis Sci. 2015 Oct;60(10):2913-22
pubmed: 25986528
Infect Control Hosp Epidemiol. 2013 Mar;34(3):302-5
pubmed: 23388366
J Investig Med. 2017 Feb;65(2):353-357
pubmed: 27737913
Infect Control Hosp Epidemiol. 2009 Apr;30(4):346-53
pubmed: 19236282
N Engl J Med. 2020 Apr 2;382(14):1320-1330
pubmed: 32242357
N Engl J Med. 2015 Feb 26;372(9):825-34
pubmed: 25714160
Am J Med. 1990 Feb;88(2):137-40
pubmed: 2301439

Auteurs

Erika M C D'Agata (EMC)

Division of Infectious Diseases, Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, USA.

Ibironke W Apata (IW)

Division of Renal Medicine, Emory University School of Medicine, Atlanta, Georgia, USA; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Stephanie Booth (S)

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

John M Boyce (JM)

J.M. Boyce Consulting, LLC, Middletown, Connecticut, USA.

Karen Deaver (K)

University of Virginia Dialysis Program, Charlottesville, Virginia, USA.

Nicole Gualandi (N)

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Alicia Neu (A)

Division of Pediatric Nephrology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Duc Nguyen (D)

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sharon Novosad (S)

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Paul M Palevsky (PM)

Renal Section, Veterans Administration Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA; Renal-Electrolyte Division, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Darlene Rodgers (D)

American Society of Nephrology Alliance for Kidney Health, Washington, DC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH